Advertisements



Bristol-Myers can be "a sweet pill" for investors, Barron"s says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 12th, 2019

Why Bristol-Myers Squibb Can Be a Sweet Pill for Investors

Wall Street has soured on the deal for Celgene, but Bristol-Myers has one of the lowest valuations in the drug sector and could itself become a takeover target.....»»

Category: topSource: barronsJan 13th, 2019

Bristol-Myers Squibb Loses $6 Billion in Value on Celgene Deal Setback: Brainstorm Health

Bristol Myers surprised investors, announcing it would spin off Celgene's popular drug Otezla to address antitrust concerns. Happy Monday, readers! Bristol-Myers Squibb hasn’t exactly had a p.....»»

Category: europeSource: fortune16 hr. 25 min. ago

Merger uncertainty and impending trials for Bristol-Myers leave investors in limbo

Investors are taking a wait-and-see approach to Bristol-Myers Squibb Co., according to Credit Suisse......»»

Category: topSource: marketwatchJun 5th, 2019

Will Bristol-Myers (BMY) Disappoint This Earnings Season?

Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) repo.....»»

Category: worldSource: nytApr 22nd, 2019

Starboard no longer urging investors to vote against Bristol-Celgene deal

Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it......»»

Category: topSource: reutersMar 29th, 2019

Celgene"s stock surges, after Starboard withdraws proxy fight of Bristol-Myers buyout deal

Shares of Celgene Corp. shot up 7.5% in very active midday trade Friday, after activist investors Starboard Value LP said it would no longer oppose the Bristol-Myers.....»»

Category: topSource: marketwatchMar 29th, 2019

Is Bristol Myers Squibb Company (BMY) A Good Stock To Buy?

The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a.....»»

Category: topSource: insidermonkeyMar 26th, 2019

Is Bristol-Myers (BMY) a Solid Pick for Value Investors?

Let's see if Bristol-Myers (BMY) stock is a good choice for value-oriented investors right now from multiple angles. Want the latest recommendations from Zacks Inve.....»»

Category: dealsSource: nytMar 11th, 2019

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Merck profit beats, but Keytruda sales fail to impress

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy......»»

Category: topSource: reutersJul 27th, 2018

Celgene shareholders should sell now, Leerink says

Bristol-Myers Squibb Co.'s agreement to acquire Celgene Corp. is "an exit opportunity for Celgene shareholders," Leerink analysts wrote in a note to investors Thur.....»»

Category: topSource: marketwatchJan 3rd, 2019

Celgene Investors Should Take the Money and Run

With Celgene stock trading 25% higher after Bristol-Myers Squibb made a $74 billion acquisition offer, Celgene investors probably shouldn’t wait around to see if the deal closes......»»

Category: topSource: barronsJan 4th, 2019

Should Investors Like Bristol-Myers" Buyout of Celgene?

The pharmaceutical giant’s $74 billion bid for the biotechnology player sent the acquirer’s shares significantly lower, but that’s hardly unusual......»»

Category: topSource: foxnewsJan 7th, 2019

Barron"s Picks And Pans: Amazon, Apple, Bristol-Myers, Starbucks And More

This weekend's Barron's cover story reveals the results of the Barron's 2019 Investment Roundtable. Other featured articles examine safe dividend growth stocks and the best stock funds for risky markets. read more.....»»

Category: blogSource: benzingaJan 13th, 2019

Here"s What Starboard Might Be Planning for Papa John"s and Bristol-Myers

The hedge fund has a history in both restaurants and in health care. It isn’t clear what Starboard CEO Jeff Smith plans this time, but investors should take note......»»

Category: topSource: barronsFeb 5th, 2019

Bristol-Myers sentiment suffered "double hit" yesterday, says William Blair

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall6 hr. 10 min. ago

Abbvie To Buy Allergan For $60 Billion In Latest Pharma Megadeal

Just months after Bristol-Myers Squibb and Celgene announced one of the biggest drug industry tie-ups in recent memory.....»»

Category: blogSource: zerohedge8 hr. 25 min. ago

S&P says Bristol-Myers Squibb rating unchanged on Otezla sale

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 24th, 2019

Bristol-Myers" merger headaches could be "contagious," STAT News says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 24th, 2019

Bristol-Myers falls -5.1%

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 24th, 2019